Effects of recombinant human brain natriuretic peptide in Non-ST-segment elevation  acute  myocardial  infarction  patients  with  heart  failure

Abstract

Abstract: AIM: To evaluate the effect and adverse reactions of recombinant human brain natriuretic peptide(rhBNP) in Non-ST-segment elevation acute myocardial infarction patients with heart failure.METHODS: Treatment group:26 cases of conventional drug therapy based on rhBNP to the treatment; Control group: 27 patients received routine treatment. Vital signs, respiratory difficulty, BNP and related changes in hemodynamics were observed before and after treatment.RESULTS: The two groups in clinical performance(including symptoms and signs),functional class,left ventricular ejection fraction,urine volume(average urine volume per hour)and so,the difference was significant (P＜0.05).CONCLUSION: rhBNP for Non-ST-segment elevation acute myocardial infarction (NSTEMI) with heart failure have a significant effect, but a low incidence of adverse reactions.

Key words: Recombinant human brain natriuretic peptide, Non-ST-segment elevation acute myocardial infarction, Heart failure

CLC Number:

R541.4

QIAO Hua, HE Sheng-hu, JI Jun, CHEN Shu, LIU Xiao-dong, XU Ri-xing, XIE Yong. Effects of recombinant human brain natriuretic peptide in Non-ST-segment elevation acute myocardial infarction patients with heart failure[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(12): 1406-1409.

References

[1] 陈纪林,高润霖,张峻,等.急性非Q波心肌梗死冠状动脉病变特点分析[J].中华心血管病杂志,2001,29(12):726-727.
[2] Kawakami R,Saito Y,Kishimoto I , et al . Over expression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction[J].Circulation ,2004 ,110(21) :3306-3312.
[3] Karl S, John C,Wlson S, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary[J].Eur Heart J, 2005, 26 (6) : 1115-1140.
[4] 马虹.重组人脑利钠肽在心力衰竭治疗中的作用[J].新医学,2007, 38 (10) : 685-687.
[5] Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide,a natriuretic pep tide, in the treatment of decompensated congestive: heart failure .Nesiritide Study Group[J]. N Engl J Med, 2000, 343(4):246-253.
[6] Emerman CL.Safety and efficacy of nesiritide for the treatment of decompensated heart failure[J]. Rev Cardiovasc Med, 2002, 3 (Suppl 4):S28-34.
[7] Peacock WF, Emerman CE, Doleh M, et al. The incidence of non-ST segment elevationMI in emergency department patients p resenting with decompensated heart failure[J]. Congest Heart Fail, 2003, 9(6): 303-308.
[8] Peacock WF 4th, Emerman CL, Young J. Nesiritide in congestive heart failure associated with acute coronary syndromes: a pilot study of safety and efficacy[J].J Card Fail, 2004, 10(2): 120-125.
[9] Peacock WF, Emerman CL, Silver MA. Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure[J].Am J Emerg Med, 2005, 23: 327-331.
[10] 吴铿,回皓声,莫振兆,等.氯沙坦联合美托洛尔治疗充血性心力衰竭的疗效观察[J]. 中国临床药理学与治疗学,1999,4(3):250-251.
[11] Zellner C, Protter AA, Ko E, et al. Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries[J]. Am J Physiol, 1999, 276 (3) : 149-157.
[12] Michaels AD, Klein A, Madden JA, et al.Effects of intravenousnesiritide on human coronary vasomotor regulation and myocardial oxygen uptake[J].Circulation, 2003, 107(21): 269-270.
[13] BurgerAJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B2 type natriuretic pep tide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study[J].Am Heart J, 2002,144(6):102-108.
[14] Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic pep tide in patients with hemodynamically decompensated heart failure[J]. J Card Fail, 1998, 4(1):37-44.
[15] Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts[J].Hypertension, 1995, 25(2): 227-234.

Effects of recombinant human brain natriuretic peptide in Non-ST-segment elevation acute myocardial infarction patients with heart failure

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
[2]	PENG Yong, FAN Jianfeng, XIONG Xuhua, XIAO Dongping, GAO Zhaobo, ZHENG Chunhua. Effect of iron dextran dispersible tablets on heart failure patients with iron deficiency [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 178-183.
[3]	CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke. Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092.
[4]	YANG Sheng, WANG Deguo. Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTnⅠ and BNP levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1010-1015.
[5]	PENG Juan, FAN Linlin, LI Ranyi, LI Xiaoyu, LV Qianzhou, ZOU Yunzeng. Progress of pharmacotherapy for heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 373-381.
[6]	LIU Ping, QIU Bo, WU Huizhen. Pharmacology and clinical evaluation of vericiguat in the treatment of heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 212-218.
[7]	XU Yonghua, SHI Xianghong. Analysis of the efficacy of torasemide combined with levocarnitine in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 647-652.
[8]	CHEN Lifang, WANG Bo, WANG Weirong. Research advances of histone deacetylase 3 in cardiovascular diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 88-97.
[9]	FAN Jianfeng，FANG Yi，ZHENG Chunhua. Clinical efficacy of sacubitril valsartan in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 810-814.
[10]	SHEN Lei, WANG Keke, YANG Jingke, ZHAO Juntao, MENG Xiangguang, YUAN Yiqiang. Advances in drugs and genetic pharmacology for heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 343-349.
[11]	WEI Zihan,LI Dongbo，YUAN Zheng,LU Ying, YANG Guojie. Clinical trial of sacubitril/valsartan in the treatment of Pulmonary hypertension (PH) due to left heart disease (LHD) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 57-62.
[12]	HUANG Ting, WANG Hegui. Research progress in regulation of heart failure by β-adrenergic-receptor-PKA-AKAP signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 592-596.
[13]	WANG Shibiao, WANG Chengyi, WENG Bin, GUO Xiaofeng, LIN Hai. Comparison of the efficacy of non-invasive USCOM and milrinone in children with severe pneumonia and heart failure and its effect on brain natriuretic peptide levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1402-1407.
[14]	LIU Yu, ZHANG Ying, WANG Ancai. Effect of rhBNP on chronic systolic heart failure combined with diuretic resistance and concentration of TNF-α and NPY [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 814-820.
[15]	WU Changjuan, TANG Tiansheng. Efficacy of Zhenyuan capsule as adjuvant therapy for chronic heart failure: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 299-304.